New pill for weight loss enters human testing
NCT ID NCT06562907
First seen Mar 25, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase study tests a new oral drug called GS-4571 in healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the body, how safe it is, and how food or acid-reducing drugs affect it. About 134 participants will take single or multiple doses, with some receiving a placebo. This is a safety and dosing trial, not yet testing if the drug works for weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
-
ICON Early Phase Services, LLC
RECRUITINGSan Antonio, Texas, 78232, United States
-
Qps-Mra, Llc.
RECRUITINGMiami, Florida, 33143, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GS-4571 (oral drug)
What this could lead to
If successful, this could lead to a new oral medication for weight management, potentially helping with obesity and type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. The drug may not work or could have side effects. Results may not apply to broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.